➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
McKinsey
Boehringer Ingelheim
Medtronic

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Perazine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Perazine?

Perazine is an investigational drug.

There have been 21 clinical trials for Perazine. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Headache, Migraine Disorders, and Schizophrenia. The leading clinical trial sponsors are Alexza Pharmaceuticals, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme (Australia) Pty Limited.

There are two hundred and sixty-three US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Perazine
TitleSponsorPhase
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsNational Cancer Institute (NCI)Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsChildren's Oncology GroupPhase 3
Paracervical Injection for Headache in the Emergency DepartmentChristian Fromm, MDPhase 2

See all Perazine clinical trials

Clinical Trial Summary for Perazine

Top disease conditions for Perazine
Top clinical trial sponsors for Perazine

See all Perazine clinical trials

US Patents for Perazine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Perazine   Start Trial COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (Baltimore, MD)   Start Trial
Perazine   Start Trial Methods of treating acanthamoeba infection using apocynin UNIVERSITY OF SOUTH FLORIDA (Tampa, FL)   Start Trial
Perazine   Start Trial Abuse-proofed dosage form GRUNENTHAL GMBH (Aachen, DE)   Start Trial
Perazine   Start Trial Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc GRUENENTHAL GMBH (Aachen, DE)   Start Trial
Perazine   Start Trial Treatment using truncated Trk B and Trk C antagonists OTONOMY, INC. (San Diego, CA)   Start Trial
Perazine   Start Trial Hot-melt extruded pharmaceutical dosage form GRUENENTHAL GMBH (Aachen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Perazine

Drugname Country Document Number Estimated Expiration Related US Patent
Perazine Canada 2975398 2035-01-30   Start Trial
Perazine European Patent Office 3250209 2035-01-30   Start Trial
Perazine Japan 2018503695 2035-01-30   Start Trial
Perazine World Intellectual Property Organization (WIPO) 2016123576 2035-01-30   Start Trial
Perazine Argentina 045352 2023-08-06   Start Trial
Perazine Argentina 045353 2023-08-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
McKinsey
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.